The prevalence and pattern of post tuberculosis lung disease including pulmonary hypertension from an Australian TB service; a single-centre, retrospective cohort study.

The prevalence and pattern of post tuberculosis lung disease including pulmonary hypertension from an Australian TB service; a single-centre, retrospective cohort study.

Publication date: Feb 21, 2025

Post Tuberculosis Lung Disease (PTLD) is increasingly recognised as a significant cause of morbidity internationally, but has not been described in an Australian setting. We aimed to determine the prevalence of PTLD among adult TB survivors from an Australian TB service and describe the pattens of lung function abnormalities and pulmonary disease, including pulmonary hypertension. We conducted a single-centre retrospective cohort study in Sydney, Australia, including all adults who successfully completed TB treatment between January 2013 and December 2022. Baseline characteristics, post treatment pulmonary function, and thoracic computed tomography (CT) data were analysed to determine the prevalence and patterns of PTLD, defined as any lung function and/or radiological abnormality attributable to TB. Among 119 confirmed TB patients (mean age 46 +/- 21 years, 61% males) PTLD was identified in 81/119 (68%). Pulmonary function testing was available for 51/119 (43%), of whom 38/51(75%) exhibited abnormalities. Obstructive deficits were found in 25/51 (49%), restrictive deficits in 11/51 (22%), and impaired gas transfer capacity in 26/51 (51%). Chest CT scans were completed in 76/119 (64%), with 70/76 (92%) demonstrating significant abnormalities, including pulmonary fibrosis 43/76 (57%), bronchiectasis 22/76 (29%), and emphysema 11/76 (15%). Pulmonary hypertension was suspected in 52/76 (68%) patients based on radiological findings. Despite successful treatment, PTLD was frequently observed among our cohort of Australian TB survivors. Further research into optimal screening practices to diagnose chronic pulmonary diseases and pulmonary hypertension could provide opportunities for earlier intervention and management.

Open Access PDF

Concepts Keywords
Australia Bronchiectasis.
Ct Pulmonary hypertension
December Tuberculosis
Males
Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH lung disease
disease MESH pulmonary hypertension
disease MESH morbidity
disease MESH abnormalities
disease MESH pulmonary fibrosis
disease MESH bronchiectasis
disease MESH emphysema
disease IDO intervention
pathway REACTOME Reproduction
disease MESH sequelae
disease MESH acute disease
disease MESH symptom burden
disease MESH chronic condition
disease MESH COPD
disease IDO history
drug DRUGBANK Fenamole
drug DRUGBANK Coenzyme M
drug DRUGBANK Ethionamide
disease MESH re infection
disease MESH relapse
drug DRUGBANK Naproxen
drug DRUGBANK Salbutamol
disease MESH total lung capacity
disease MESH hypertension
disease MESH infection
drug DRUGBANK Rifampicin
drug DRUGBANK Isoniazid
drug DRUGBANK Pyrazinamide
disease MESH Cystic Fibrosis
disease MESH Pulmonary embolism
disease MESH Obstructive sleep apnea
drug DRUGBANK Methyprylon
disease MESH fibrosis
disease MESH lymphadenopathy
disease IDO drug susceptibility
drug DRUGBANK Carbon monoxide
drug DRUGBANK Iron
drug DRUGBANK Spinosad
disease MESH clinical significance
drug DRUGBANK Trestolone
drug DRUGBANK Bentiromide
disease MESH obstructive lung disease
disease MESH interstitial lung diseases
disease MESH asthma
pathway KEGG Asthma
disease MESH Long COVID
disease IDO host
disease IDO pathogen
disease MESH malnutrition
drug DRUGBANK Etoperidone
disease MESH pulmonary tuberculosis
drug DRUGBANK Platinum

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *